As mentioned above, it has been reported that the effect of ICIs on tumor treatment is not significant for large or rapidly growing tumors.[37] Therefore, a significant reduction in tumor volume by the FOXM1 inhibitor, in addition to its effect on PD‐L1 expression, could be an important factor in enhancing the therapeutic outcome of immunotherapy in lung cancer. This evidence concerns the gene FOXM1 and lung cancer.